Point.JPG
POINT Biopharma Adds Senior BD Expertise with Appointment of Dr. Matthew Vincent as SVP, Business Development
04 janv. 2022 08h30 HE | POINT Biopharma
INDIANAPOLIS, Jan. 04, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life...
Point.JPG
POINT Biopharma adds a COO, Further Strengthens Leadership Team, and Announces Additional Board and Leadership Changes
01 déc. 2021 08h30 HE | POINT Biopharma
Justyna Kelly promoted to COO, Dr. Robin Hallett promoted to VP, Discovery and Translational Sciences, Dr. Sherin Al-Safadi to join as VP Medical Affairs, and Michael Gottlieb (CCO) to depart the...
Point.JPG
POINT Biopharma Licenses Innovative Lu-177 Production Technology from SCK CEN (Belgian Nuclear Research Center)
24 nov. 2021 08h30 HE | POINT Biopharma
INDIANAPOLIS and MOL, Belgium , Nov. 24, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT), a company accelerating the discovery, development, and global access to life changing...
Point.JPG
POINT Biopharma to Host Virtual Education Event on December 6, 2021
22 nov. 2021 08h30 HE | POINT Biopharma
POINT to host inaugural educational event highlighting radiopharmaceuticals, their therapeutic benefit, and commercial considerations Register online at https://hub.pointbiopharma.com/dec2021 ...
Point.JPG
POINT Biopharma Reports Third Quarter 2021 Financial Results and Provides Business Update
12 nov. 2021 08h30 HE | POINT Biopharma
Initiated randomization phase of Phase 3 SPLASH study of PNT2002 in patients with metastatic castration-resistant prostate cancer (mCRPC) Expanded FAP alpha inhibitor platform and on track to file an...
Point.JPG
POINT Biopharma and IONETIX Announce Ac-225 Supply Agreement
09 nov. 2021 08h30 HE | POINT Biopharma
INDIANAPOLIS and TORONTO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT), a company accelerating the discovery, development, and global access to life changing...
Point.JPG
POINT Biopharma and Kinectrics Announce Yb-176 Supply Agreement Enabling North American Production of n.c.a. Lu-177
29 oct. 2021 08h30 HE | POINT Biopharma
POINT to host inaugural educational event highlighting radiopharmaceuticals, their therapeutic benefit, and commercial considerations on Dec 6, 2021 – register online at...
Point.JPG
POINT Biopharma Releases New Data and Exercises Option for Best-in-Class FAP Inhibitor
28 sept. 2021 08h00 HE | POINT Biopharma
Unique FAP targeting warhead combined with Actinium-225 or Lutetium-177 demonstrated complete tumor regression and long-term survival in preclinical models Initiation of a Phase 1 therapeutic...
Point.JPG
POINT Biopharma Announces Initiation of Randomization for its Phase 3 SPLASH study Evaluating PNT2002 for mCRPC
23 sept. 2021 08h00 HE | POINT Biopharma
25 patient dosimetry and safety run-in met all pre-specified safety and efficacy criteria Initiated patient enrollment in Canada with additional countries to begin enrolling in 4Q21 INDIANAPOLIS,...
Point.JPG
POINT Biopharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
07 sept. 2021 08h00 HE | POINT Biopharma
INDIANAPOLIS, Sept. 07, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to life...